0000899243-20-018277.txt : 20200702
0000899243-20-018277.hdr.sgml : 20200702
20200702161834
ACCESSION NUMBER: 0000899243-20-018277
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200630
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tucker John H
CENTRAL INDEX KEY: 0001303480
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38293
FILM NUMBER: 201009573
MAIL ADDRESS:
STREET 1: INDEVUS PHARMACEUTICALS, INC.
STREET 2: 99 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: scPharmaceuticals Inc.
CENTRAL INDEX KEY: 0001604950
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465184075
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2400 DISTRICT AVENUE
STREET 2: SUITE 310
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: 617-517-0730
MAIL ADDRESS:
STREET 1: 2400 DISTRICT AVENUE
STREET 2: SUITE 310
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-30
0
0001604950
scPharmaceuticals Inc.
SCPH
0001303480
Tucker John H
C/O SCPHARMACEUTICALS INC.
2400 DISTRICT AVENUE, SUITE 310
BURLINGTON
MA
01803
1
1
0
0
President and CEO
Common Stock
2020-06-30
4
M
0
42250
A
47250
D
Common Stock
2020-06-30
4
F
0
10288
7.36
D
36962
D
Restricted Stock Units
2020-06-30
4
M
0
42250
0.00
D
Common Stock
42250
0
D
Stock Option (right to buy)
3.25
2020-06-30
4
A
0
42250
0.00
A
2029-02-25
Common Stock
42250
42250
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.
On February 25, 2019, the Reporting Person was granted 84,500 restricted stock units (the "RSUs"). One half (1/2) of the RSUs shall vest upon the Issuer's submission of a New Drug Application ("NDA") for its product candidate, FUROSCIX and the remaining one half (1/2) shall vest upon the Food & Drug Administration's (the "FDA") approval of the NDA. On June 30, 2020, the performance criteria for the first half of the grant was met and 42,250 shares vested.
On February 25, 2019, the Reporting Person was granted an option to purchase 84,500 shares of common stock. One half (1/2) of the shares shall vest upon the Issuer's submission of an NDA for its product candidate, FUROSCIX and the remaining one half (1/2) shall vest upon the FDA's approval of the NDA. On June 30, 2020, the performance criteria for the first half of the grant was met and 42,250 shares vested.
/s/ John Tucker
2020-07-02